IBI322
innovent biologics
['hodgkin', 'lymphoma', 'innovent']
innovent announces phase 1 clinical data of ibi322 (cd47/pd-l1 bispecific antibody) in the treatment of anti-pd-(l)1-resistant classic hodgkin lymphoma patients at the eha 2023 annual meeting #prnewswire #prnewswire 
Stock Market News and Press Releases. #StockMarket & #Crypto